As the federal government continues to grapple with the issue of illicit drugs, a significant focus is being placed on developing the 2026 National Drug Control Strategy. This strategy aims to address drug use across the nation by incorporating various policy priorities.
The R Street Institute has recently put forth recommendations for this strategy, urging the Office of National Drug Control Policy (ONDCP) to emphasize demand-reducing strategies alongside efforts to control supply. The institute argues that while supply-side interventions can reduce the influx of drugs into the country, they are insufficient on their own, especially with easily produced substances like fentanyl.
R Street highlights that prevention and treatment are crucial in reducing demand for illicit drugs. The Drug Policy Priorities stress preventing initial drug use and increasing access to evidence-based treatment for long-term recovery. However, accessing treatment remains challenging due to capacity issues and limited services, particularly in rural areas.
Harm reduction is presented as a key element in bridging the gap between prevention and treatment. It aims to decrease health risks associated with drug use and guide individuals towards treatment when they are ready. This approach is seen as essential in a comprehensive drug control strategy.
The R Street Institute’s recommendations include supporting community-based naloxone distribution programs, streamlining regulations for medications used in opioid disorder treatments, producing guidance on new treatments for stimulant use disorder, addressing gaps between prevention and treatment through harm reduction services, providing guidance on using opioid settlement funds effectively, and reducing limitations on state block grants.
The institute emphasizes that a multifaceted approach is necessary to tackle both supply and demand aspects of drug policy effectively.
